CCCC
C4 Therapeutics, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$3.37Close
$326.6MMarket cap
$1.71 – $4.6752-week range
Nov 5, 2026Next report
Highlights
Strengths
- Leading the market RS 80 · stronger than 80% of stocks over 12 months
Cautions
- Not in an uptrend 5 of 8 trend conditions
- Far from its high 28% below its 52-week high
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
28%
1wk
up 10.1%
price change
1mo
up 1.2%
price change
12-month return
up 37%
market up 11% ·
its own up 23%
F-score
—
— Not assessed
Altman Z
-1.17
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
1.3×
price / book
Earnings yield
down 45.7%
EBIT / enterprise value
Cheaper than
30%
of the market · expensive
Revenue growth
up 1%
year on year
EPS growth
—
latest quarter
Sales growth
up 3%
latest quarter · +18 pts
ROE
down 44%
return on equity
Free cash margin
down 276%
-$99.3M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
6.4%
$0.21 a day · 2×ATR $2.94
RS
80 / 99
vs the universe
Trend
5 / 8
under the 150/200-day, 50-day under the 150/200-day, over 25% off the high
Relative volume
1.0×
vs 50-day average
Up/down volume
0.89
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 5 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: passes
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 37.2% over the year, from 71m to 97m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 11, 2026
Results reaction
Aug 11, 2026+8% vs market2 sessions after results
Financials
- Net -292%
- Free cash -276%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | — | $45.8M | $31.1M | $20.8M | $35.6M | $35.9M |
| Operating income | -$60.4M | -$82.1M | -$129.5M | -$139.0M | -$119.6M | -$115.2M |
| Net income | -$66.3M | -$83.9M | -$128.2M | -$132.5M | -$105.3M | -$105.0M |
| Net margin | — | -183% | -412% | -638% | -296% | -292% |
| Earnings per share | — | -$1.82 | -$2.62 | -$2.67 | -$1.52 | -$1.27 |
| Free cash flow | -$67.9M | -$88.2M | -$111.4M | -$108.5M | -$65.3M | -$99.3M |
| Free cash margin | — | -193% | -358% | -523% | -184% | -276% |
| Cash | $181.7M | $76.1M | $29.8M | $126.6M | $55.5M | $74.6M |
| Long-term debt | $10.1M | $10.8M | $9.2M | $0 | — | — |
| Shareholders' equity | $280.8M | $389.6M | $289.2M | $246.1M | $216.0M | $256.6M |
| Shares outstanding | 43.06m | 48.69m | 48.97m | 60.47m | 70.63m | 96.91m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 11, 2026 | Quarterly ↗ | Jun 30, 2026 | 42d |
| May 12, 2026 | Quarterly ↗ | Mar 31, 2026 | 42d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 7, 2025 | Quarterly ↗ | Mar 31, 2025 | 37d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Oct 31, 2024 | Quarterly ↗ | Sep 30, 2024 | 31d |
| Aug 1, 2024 | Quarterly ↗ | Jun 30, 2024 | 32d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Feb 22, 2024 | Annual ↗ | Dec 31, 2023 | 53d |
| Nov 1, 2023 | Quarterly ↗ | Sep 30, 2023 | 32d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 25, 2026 | Regulation FD · Other events ↗ |
| Aug 11, 2026 | Results ↗ |
| Jun 24, 2026 | Shareholder vote ↗ |
| Jun 11, 2026 | Regulation FD · Other events ↗ |
| May 15, 2026 | Director or officer change ↗ |
| May 12, 2026 | Results · Regulation FD ↗ |
| Apr 10, 2026 | Charter or bylaws ↗ |
| Apr 9, 2026 | Material agreement · Regulation FD ↗ |
| Feb 26, 2026 | Results ↗ |
| Jan 14, 2026 | Regulation FD ↗ |
| Nov 6, 2025 | Results ↗ |
| Oct 16, 2025 | Other events ↗ |